Home›Haloperidol Decanoate

Haloperidol Decanoate

Also known as: Haloperidol Decanoate

Route: Intramuscular

Check Haloperidol Decanoate Interactions →

35 interactions on record⛔ Black Box Warning

Haloperidol Decanoate has 35 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cns Depressants, Drugs That Prolong Qtc Interval, Drugs That Prolong The Qt Interval. Patients taking Haloperidol Decanoate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 35
Major: 6
Moderate: 28
Minor: 1

Major (6)

Haloperidol Decanoate + Cns Depressants— Haloperidol may potentiate CNS depressants including anesthetics, opioids, and alcohol.
Haloperidol Decanoate + Drugs That Prolong Qtc Interval— Concomitant use may result in greater QTc interval prolongation and adverse reactions including torsade de pointes, seri…
Haloperidol Decanoate + Drugs That Prolong The Qt Interval— Concomitant use may result in greater QTc interval prolongation and serious adverse reactions including torsade de point…
Haloperidol Decanoate + Ketoconazole— CYP3A4 inhibitor that significantly increases haloperidol concentrations; increased QTc prolongation observed when combi…
Haloperidol Decanoate + Paroxetine— CYP2D6 inhibitor that increases haloperidol concentrations; significant QTc prolongation observed when combined with ket…
Haloperidol Decanoate + Topical Local Anesthetics— Haloperidol may potentiate CNS depressants, increasing risk of enhanced CNS depression.

Moderate (28)

Haloperidol Decanoate + Alcohol— CNS depressant that may be potentiated by haloperidol decanoate; monitor for combined CNS depression effects.
Haloperidol Decanoate + Alprazolam— CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Amiodarone— Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk o…
Haloperidol Decanoate + Buspirone— Increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation and dose r…
Haloperidol Decanoate + Chlorpromazine— CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Citalopram— Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.
Haloperidol Decanoate + Corticosteroids— May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalc…
Haloperidol Decanoate + Cyp3a Inducers— CYP3A4 inducers decrease haloperidol exposure and may reduce the effectiveness of haloperidol decanoate. Monitor patient…
Haloperidol Decanoate + Disopyramide— Class 1A antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk …
Haloperidol Decanoate + Diuretics— May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalc…
Haloperidol Decanoate + Dopamine Agonists— Haloperidol may antagonize the effects of dopamine agonists and other drugs intended to increase dopamine levels.
Haloperidol Decanoate + Erythromycin— Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.
Haloperidol Decanoate + Fluoxetine— Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse eff…
Haloperidol Decanoate + Fluvoxamine— Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse eff…
Haloperidol Decanoate + Itraconazole— CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Levodopa— Haloperidol may antagonize the effects of levodopa and reduce its therapeutic effectiveness.
Haloperidol Decanoate + Levofloxacin— Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.
Haloperidol Decanoate + Methadone— Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.
Haloperidol Decanoate + Nefazodone— CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Procainamide— Class 1A antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk …
Haloperidol Decanoate + Promethazine— CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Quinidine— Class 1A antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk …
Haloperidol Decanoate + Ritonavir— Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse eff…
Haloperidol Decanoate + Sertraline— CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Silver Preparations— Inhibitors increase haloperidol exposure, which may increase risk of haloperidol-associated adverse reactions. Monitor f…
Haloperidol Decanoate + Sotalol— Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk o…
Haloperidol Decanoate + Venlafaxine— CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc p…
Haloperidol Decanoate + Ziprasidone— Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Minor (1)

Haloperidol Decanoate + Valproate Sodium— Inhibits glucuronidation but does not affect haloperidol plasma concentrations; no clinically significant interaction.

Haloperidol Decanoate + Cns Depressants⚠️Major

Haloperidol may potentiate CNS depressants including anesthetics, opioids, and alcohol.

Haloperidol Decanoate + Drugs That Prolong Qtc Interval⚠️Major

Concomitant use may result in greater QTc interval prolongation and adverse reactions including torsade de pointes, serious arrhythmias, and sudden death.

Haloperidol Decanoate + Drugs That Prolong The Qt Interval⚠️Major

Concomitant use may result in greater QTc interval prolongation and serious adverse reactions including torsade de pointes, other serious arrhythmias, and sudden death.

Haloperidol Decanoate + Ketoconazole⚠️Major

CYP3A4 inhibitor that significantly increases haloperidol concentrations; increased QTc prolongation observed when combined with paroxetine.

Haloperidol Decanoate + Paroxetine⚠️Major

CYP2D6 inhibitor that increases haloperidol concentrations; significant QTc prolongation observed when combined with ketoconazole.

Haloperidol Decanoate + Topical Local Anesthetics⚠️Major

Haloperidol may potentiate CNS depressants, increasing risk of enhanced CNS depression.

Haloperidol Decanoate + Alcohol🟡Moderate

CNS depressant that may be potentiated by haloperidol decanoate; monitor for combined CNS depression effects.

Haloperidol Decanoate + Alprazolam🟡Moderate

CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Amiodarone🟡Moderate

Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Buspirone🟡Moderate

Increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation and dose reduction may be necessary.

Haloperidol Decanoate + Chlorpromazine🟡Moderate

CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Citalopram🟡Moderate

Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Corticosteroids🟡Moderate

May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalcemia increase QT prolongation risk.

Haloperidol Decanoate + Cyp3a Inducers🟡Moderate

CYP3A4 inducers decrease haloperidol exposure and may reduce the effectiveness of haloperidol decanoate. Monitor patients and increase dosage if necessary.

Haloperidol Decanoate + Disopyramide🟡Moderate

Class 1A antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Diuretics🟡Moderate

May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalcemia increase QT prolongation risk.

Haloperidol Decanoate + Dopamine Agonists🟡Moderate

Haloperidol may antagonize the effects of dopamine agonists and other drugs intended to increase dopamine levels.

Haloperidol Decanoate + Erythromycin🟡Moderate

Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Fluoxetine🟡Moderate

Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Fluvoxamine🟡Moderate

Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Itraconazole🟡Moderate

CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Levodopa🟡Moderate

Haloperidol may antagonize the effects of levodopa and reduce its therapeutic effectiveness.

Haloperidol Decanoate + Levofloxacin🟡Moderate

Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Methadone🟡Moderate

Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Nefazodone🟡Moderate

CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Procainamide🟡Moderate

Class 1A antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Promethazine🟡Moderate

CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Quinidine🟡Moderate

Class 1A antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Ritonavir🟡Moderate

Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Sertraline🟡Moderate

CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Silver Preparations🟡Moderate

Inhibitors increase haloperidol exposure, which may increase risk of haloperidol-associated adverse reactions. Monitor for increased or prolonged pharmacologic effects.

Haloperidol Decanoate + Sotalol🟡Moderate

Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Venlafaxine🟡Moderate

CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Haloperidol Decanoate + Ziprasidone🟡Moderate

Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Haloperidol Decanoate + Valproate Sodium🟢Minor

Inhibits glucuronidation but does not affect haloperidol plasma concentrations; no clinically significant interaction.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.